Meeting
2021 Genitourinary Cancers Symposium
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.
Authors
Michael Szarek
SUNY Downstate Medical Center, Brooklyn, NY
Michael Szarek , Michael N. Needle , Brian I. Rini , Sumanta K. Pal , David F. McDermott , Michael B. Atkins , Thomas E. Hutson , Bernard Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Clinical Trial Registration Number
NCT02627963
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 298)
DOI
10.1200/JCO.2021.39.6_suppl.298
Abstract #
298
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2018 Gastrointestinal Cancers Symposium
Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
First Author: Sunyoung S. Lee
Poster
2017 ASCO Annual Meeting
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
First Author: Carissa Beaulieu